Literature DB >> 12846921

The drug budget silo mentality in Europe: an overview.

Lou Garrison1, Adrian Towse.   

Abstract

Mesh：

Year:  2003        PMID： 12846921     DOI： 10.1046/j.1524-4733.6.s1.1.x

Source DB:  PubMed          Journal:  Value Health        ISSN： 1098-3015            Impact factor:   5.725


× No keyword cloud information.
  12 in total

1.  Points to consider in assessing and appraising predictive genetic tests.

Authors:  Wolf H Rogowski; Scott D Grosse; Jürgen John; Helena Kääriäinen; Alastair Kent; Ulf Kristofferson; Jörg Schmidtke
Journal:  J Community Genet       Date:  2010-10-16

Review 2.  Pharmacoeconomics: friend or foe?

Authors:  M Drummond
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

3.  Doctors' attitudes about prescribing and knowledge of the costs of common medications.

Authors:  C McGuire; S King; G Roche-Nagle; M C Barry
Journal:  Ir J Med Sci       Date:  2009-02-17       Impact factor: 1.568

4.  Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

Authors:  Adrian Towse; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 5.  Defining and Measuring the Affordability of New Medicines: A Systematic Review.

Authors:  Fernando Antoñanzas; Robert Terkola; Paul M Overton; Natalie Shalet; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

6.  Do randomized controlled trials discuss healthcare costs?

Authors:  G Michael Allan; Christina Korownyk; Kate LaSalle; Ben Vandermeer; Victoria Ma; Douglas Klein; Donna Manca
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

Review 7.  Pharmaceutical policies: effects of financial incentives for prescribers.

Authors:  Arash Rashidian; Amir-Houshang Omidvari; Yasaman Vali; Heidrun Sturm; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2015-08-04

8.  The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.

Authors:  Chi-Liang Chen; Likwang Chen; Wei-Chih Yang
Journal:  BMC Public Health       Date:  2008-04-12       Impact factor: 3.295

9.  Value added medicines: what value repurposed medicines might bring to society?

Authors:  Mondher Toumi; Cécile Rémuzat
Journal:  J Mark Access Health Policy       Date:  2016-12-23

Review 10.  Physician awareness of drug cost: a systematic review.

Authors:  G Michael Allan; Joel Lexchin; Natasha Wiebe
Journal:  PLoS Med       Date:  2007-09       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.